131
Participants
Start Date
December 9, 2022
Primary Completion Date
March 7, 2025
Study Completion Date
March 7, 2025
Ozanimod
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0061, Changzhou
Local Institution - 0060, Taipei City
Local Institution - 0058, New Taipei City
Local Institution - 0055, Taoyuan District
Local Institution - 0059, Taichung
Local Institution - 0056, Taipei
Local Institution - 0057, Taipei
Local Institution - 0001, Taichung
Local Institution - 0054, Changhua County
Local Institution - 0052, Beijing
Local Institution - 0010, Shenyang
Local Institution - 0035, Shanghai
Local Institution - 0041, Shanghai
Local Institution - 0034, Shanghai
Local Institution - 0053, Shanghai
Local Institution - 0024, Nanjing
Local Institution - 0045, Nanjing
Local Institution - 0042, Zhenjiang
Local Institution - 0046, Changzhou
Local Institution - 0044, Wuxi
Local Institution - 0018, Suzhou
Local Institution - 0009, Suzhou
Local Institution - 0012, Hefei
Local Institution - 0013, Wuhu
Local Institution - 0039, Jinan
Local Institution - 0031, Tianjin
Local Institution - 0047, Tianjin
Local Institution - 0030, Hangzhou
Local Institution - 0048, Fuzhou
Local Institution - 0011, Xiamen
Local Institution - 0050, Chongqing
Local Institution - 0027, Changsha
Local Institution - 0022, Changsha
Local Institution - 0040, Wuhan
Local Institution - 0037, Wuhan
Local Institution - 0033, Wuhan
Local Institution - 0020, Guangzhou
Local Institution - 0036, Guangzhou
Local Institution - 0028, Guangzhou
Local Institution - 0019, Guangzhou
Local Institution - 0008, Guangzhou
Local Institution - 0004, Zhanjiang
Local Institution - 0051, Guilin
Local Institution - 0032, Chengdu
Local Institution - 0025, Chengdu
Local Institution - 0049, Kunming
Local Institution - 0029, Xi'an
Local Institution - 0026, Xi'an
Local Institution - 0007, Shijiazhuang
Local Institution - 0006, Shijiazhuang
Local Institution - 0015, Taiyuan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY